Heimo Syvala

Tampere, Finland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

The Impact of Atorvastatin on Intraprostatic Biomarkers - Prognostic Value of 3LS-score - Follow-up of ESTO1-Trial.

The Impact of Atorvastatin on Intraprostatic Biomarkers - Prognostic Value of 3LS-score - Follow-up of ESTO1-Trial.

Journal: Neoplasia (New York, N.Y.)
Published: June 05, 2024

Role of Lipids and Lipid Metabolism in Prostate Cancer Progression and the Tumor's Immune Environment.

Role of Lipids and Lipid Metabolism in Prostate Cancer Progression and the Tumor's Immune Environment.

Journal: Cancers
Published: July 06, 2022

Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation.

Adaptive and non-adaptive gene expression responses in prostate cancer during androgen deprivation.

Journal: PloS one
Published: June 07, 2022

Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse.

Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse.

Journal: Nature communications
Published: April 01, 2021

Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial.

Atorvastatin induces adrenal androgen downshift in men with prostate cancer: A post Hoc analysis of a pilot adaptive Randomised clinical trial.

Journal: EBioMedicine
Published: February 19, 2021

Circulatory and prostatic tissue lipidomic profiles shifts after high-dose atorvastatin use in men with prostate cancer.

Circulatory and prostatic tissue lipidomic profiles shifts after high-dose atorvastatin use in men with prostate cancer.

Journal: Scientific reports
Published: December 04, 2019

Reply to Jae Heon Kim and Benjamin I. Chung's Letter to the Editor re: Teemu J. Murtola, Heimo Syvälä, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701.

Reply to Jae Heon Kim and Benjamin I. Chung's Letter to the Editor re: Teemu J. Murtola, Heimo Syvälä, Teemu Tolonen, et al. Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. Eur Urol 2018;74:697-701.

Journal: European urology
Published: January 20, 2019

Access and concentrations of atorvastatin in the prostate in men with prostate cancer.

Access and concentrations of atorvastatin in the prostate in men with prostate cancer.

Journal: The Prostate
Published: December 10, 2018

Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.

Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial.

Journal: European urology
Published: December 16, 2017

Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells.

Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells.

Journal: Biochemical and biophysical research communications
Published: October 31, 2016

The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines.

The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines.

Journal: European journal of pharmacology
Published: May 26, 2016

The importance of LDL and cholesterol metabolism for prostate epithelial cell growth.

The importance of LDL and cholesterol metabolism for prostate epithelial cell growth.

Journal: PloS one
Published: December 25, 2011
Showing 1-12 of 12

Last Updated: 09/26/2026